Bayer HealthCare Pharmaceuticals
Bayer Pharma AG
Dr. Luisella Toschi
Bayer Pharma AG, the Berlin-based prescription-medicine division of Bayer Health Care and thereby part of Bayer AG, is a major global pharmaceutical company with more than 38.000 employees of which more than 5.600 work in R&D. BPH has a long standing expertise and track record in the development of drugs targeting neo-angiogenesis driven by Vascular Endothelial Growth Factor (VEGF) Receptor activation in cancer patients. The small-molecule (SMOL) kinase inhibitor Nexavar/Sorafenib is approved for treatment of renal cell and hepatocellular carcinoma and accounted for net sales of 462 Million € in 2008. Furthermore, another SMOL kinase inhibitors Vatalanib/PTK787/ZK222584 was co-developed with Novartis. More recently, Regorafenib, a multi-tyrosine receptor kinase inhibitor, has been approved by FDA for the treatment of CRC. BPH oncology area focuses now on four main indications: Cell Cycle & Survival Signalling, Immunotherapy & Antibody-Drug Conjugate, Chromatin Modulation & Oncogenomics, Tumor Metabolism & Hypoxia. Women Healthcare area has a major focus on endometriosis. Technology units provide state-of-the-art support in the generation of tool compounds and antibodies for Target Research and pharmacological studies. Screening and assay development units, pharmacokinetics, structural biologists and bioinformaticians are located at the Berlin site and collaborate closely with oncology research. In the in vivo facilities, a wide variety of tumour models covering many solid tumour indications is established. A world-wide collaborative network of academic institutions including the German Cancer Research Center (DKFZ) and key opinion leaders in oncology research collaborate with BPH oncology in the development of new model systems and drug target validation.